AlphaCrest Capital Management’s Denali Therapeutics DNLI Stock Holding History

AlphaCrest Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-20,234	Closed	-$621K	–	324
2022 Q3	$621K	Buy	20,234 +6,934	+52%	+$225K	0.04%	879
2022 Q2	$391K	Sell	13,300 -13,900	-51%	-$364K	0.02%	1031
2022 Q1	$875K	Buy	27,200 +17,389	+177%	+$598K	0.05%	616
2021 Q4	$438K	Buy	9,811 +3,411	+53%	+$162K	0.02%	1147
2021 Q3	$323K	Buy	+6,400	New	+$361K	0.02%	1077
2021 Q2	–	Sell	-13,400	Closed	-$765K	–	1244
2021 Q1	$765K	Buy	+13,400	New	+$897K	0.04%	615
2020 Q3	–	Sell	-16,900	Closed	-$409K	–	1113
2020 Q2	$409K	Buy	+16,900	New	+$397K	0.07%	471
2019 Q4	–	Sell	-14,100	Closed	-$216K	–	1268
2019 Q3	$216K	Buy	+14,100	New	+$269K	0.01%	1196

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

AlphaCrest Capital Management's DNLI Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Denali Therapeutics (DNLI) in Q4 2022, closing a stake of 20,234 shares — an estimated $621K sold.

AlphaCrest Capital Management first reported a position in DNLI in Q3 2019 and held it in 8 quarters. The position peaked at $875K in Q1 2022. 199 funds tracked by Wall St. Rank hold DNLI as of Q4 2022.

AlphaCrest Capital Management reported no remaining Denali Therapeutics position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 20,234 Denali Therapeutics shares in Q4 2022, an estimated $621K.
AlphaCrest Capital Management first reported a position in Denali Therapeutics in Q3 2019 and held it in 8 quarters.
AlphaCrest Capital Management's Denali Therapeutics position peaked at $875K in Q1 2022.
199 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.